In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
BUSINESS
Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market
Daiichi Sankyo said on January 7 that it has launched its HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in the US for the treatment of certain patients with advanced breast cancer. Enhertu, previously known with the code DS-8201, gained…
To read the full story
Related Article
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- Daiichi Sankyo’s DS-8201 Hits Primary Target in PII Gastric Cancer Trial
January 28, 2020
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
BUSINESS
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
- Increased Off-Year Pressure on LLPs Would Only Exacerbate Supply Crunch: Industry Officials
December 24, 2024
- Eisai/Fujirebio Tie Up in Biomarker Research for Neurodegenerative Diseases
December 24, 2024
- Orion Now MA Holder of Parkinson’s Meds Stalevo, Comtan in Japan
December 24, 2024
- Shionogi to Take Full Control of 2 China Joint Ventures
December 24, 2024
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…